BeOne Medicines jumps as Wolfe starts coverage Outperform, flags 2026 catalysts
ONC•BeOne Medicines (ONC) is rising after a fresh bullish initiation from Wolfe Research with an Outperform rating and a $340 price target. The call highlights multiple 2026 clinical/regulatory catalysts, including potential sonrotoclax U.S. approval in relapsed/refractory mantle cell lymphoma in the first half of 2026.
1. What’s moving the stock
BeOne Medicines Ltd. ADS (ONC) is trading higher as investors react to a new bullish analyst initiation. Wolfe Research initiated coverage with an Outperform rating and set a $340 price target, framing BeOne as a scaled, profitable oncology company with multiple near-term catalysts that could re-rate the stock.
2. Why the initiation matters
Wolfe’s thesis centers on breadth and execution speed across BeOne’s oncology pipeline and on the durability of BRUKINSA’s position in chronic lymphocytic leukemia (CLL). The note also points to a 2026 catalyst calendar that includes potential U.S. approval for sonrotoclax in relapsed/refractory mantle cell lymphoma in the first half of 2026, plus additional Phase 3 data events later in the year—creating a steady stream of potential “headline” moments that can drive incremental buyers into the name.
3. What investors will watch next
Traders will likely look for follow-through via additional analyst actions, conference presentations, or clinical/regulatory updates tied to the 2026 milestones highlighted in the initiation. With the stock already moving, investors will also monitor whether broader biotech sentiment and risk appetite support continued multiple expansion, or whether the shares revert absent new data-driven developments.
